title: Why do clinical trials of Xpert® MTB/RIF fail to show an effect on patient relevant outcomes?
authors.affiliation: Department of Medicine, University of Cape Town, Cape Town, South Africa.
authors.forename: T H
authors.initials: TH
authors.lastname: Boyles
mesh_terms: D000904:Antibiotics, Antitubercular / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D060888:Real-Time Polymerase Chain Reaction; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology
chemical_list: D000904:Antibiotics, Antitubercular; D012293:Rifampin